Aardvark Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Aardvark Therapeutics has voluntarily halted enrollment and dosing in its pivotal Phase 3 HERO trial for ARD-101 and Phase 2 ARD-201 trials following reversible cardiac observations in a healthy volunteer study, leading to significant stock price decline.
NASDAQ
Aardvark Therapeutics, a clinical-stage biopharmaceutical company, details its financial performance for 2024 and outlines key developments in its clinical programs, including the initiation of a Phase 3 trial for ARD-101.